Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.
10.1007/s11684-021-0914-x
- Author:
Yuntao ZHANG
1
;
Yunkai YANG
1
;
Niu QIAO
2
;
Xuewei WANG
1
;
Ling DING
3
;
Xiujuan ZHU
3
;
Yu LIANG
4
;
Zibo HAN
4
;
Feng LIU
2
;
Xinxin ZHANG
5
;
Xiaoming YANG
6
Author Information
1. China National Biotec Group Company Limited, Beijing, 100024, China.
2. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
3. Beijing Institute of Biological Products, China National Biotec Group Company Limited, Beijing, 100176, China.
4. National Vaccine and Serum Institute, China National Biotec Group Company Limited, Beijing, 101111, China.
5. Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. zhangx@shsmu.edu.cn.
6. China National Biotec Group Company Limited, Beijing, 100024, China. yangxiaoming@sinopharm.com.
- Publication Type:Journal Article
- Keywords:
COVID-19;
SARS-CoV-2;
booster immunization;
immunization;
vaccine
- MeSH:
Adolescent;
Adult;
Antibodies, Neutralizing;
Antibodies, Viral;
COVID-19/prevention & control*;
COVID-19 Vaccines/adverse effects*;
China;
Humans;
Immunogenicity, Vaccine;
Middle Aged;
SARS-CoV-2;
Vaccination;
Young Adult
- From:
Frontiers of Medicine
2022;16(1):93-101
- CountryChina
- Language:English
-
Abstract:
Inducing durable and effective immunity against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) via vaccination is essential to combat the current pandemic of coronavirus disease 2019 (COVID-19). It has been noticed that the strength of anti-COVID-19 vaccination-induced immunity fades over time, which calls for an additional vaccination regime, as known as booster immunization, to restore immunity among previously vaccinated populations. Here we report a pilot open-label trial of a third dose of BBIBP-CorV, an inactivated SARS-CoV-2 vaccine (Vero cell), on 136 participants aged between 18 to 63 years. Safety and immunogenicity in terms of neutralizing antibody titers and cytokine/chemokine responses were analyzed as the main endpoint until day 28. While systemic reactogenicity was either absent or mild, SARS-CoV-2-specific neutralizing antibody titers rapidly arose in all participants within 4 weeks, surpassing the peak antibody titers elicited by the initial two-dose immunization regime. Broad increases of cellular immunity-associated cytokines and chemokines were also detected in the majority of participants after the third vaccination. Furthermore, in an exploratory study, a newly developed recombinant protein vaccine, NVSI-06-08 (CHO Cells), was found to be safe and even more effective than BBIBP-CorV in eliciting humoral immune responses in BBIBP-CorV-primed individuals. Together, these results indicate that a third immunization schedule with either homologous or heterologous vaccine showed favorable safety profiles and restored potent SARS-CoV-2-specific immunity, providing support for further trials of booster vaccination in larger populations.
